Medifast director Kiai Parsa acquired 43,150 shares of the company on August 26, 2026, for a total of $529,157 at an average price of $12.2632 per share. The transaction price ranged from $12.12 to $12.38, with the stock trading at $12.29 at the time of reporting.
Parsa’s purchase follows a 1.76% weekly gain and a 15.48% increase over the past six months for Medifast shares. Through Steamboat Capital Partners entities, Parsa already holds indirect beneficial ownership of 707,492 shares via Steamboat Capital Partners Master Fund, LP and an additional 20,270 shares via Steamboat Capital Partners II, LP. Parsa disclaimed beneficial ownership beyond his pecuniary interest in the securities.
The director’s acquisition coincides with Medifast’s second-quarter 2026 results, which reported a narrower-than-expected loss of $0.28 per share against a forecasted loss of $0.43. Revenue reached $76.4 million, exceeding the anticipated $74.7 million. The company also noted a significant decline in active coaches but highlighted productivity improvements and positive reception for its new Trilivy brand.
